(Q45918280)

17 December 2017

title

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. (English)

1 reference

17 December 2017

author name string

B Laika

1

1 reference

17 December 2017

S Leucht

2

1 reference

17 December 2017

S Heres

3

1 reference

17 December 2017

H Schneider

4

1 reference

17 December 2017

W Steimer

5

1 reference

17 December 2017

publication date

28 July 2009

1 reference

17 December 2017

The Pharmacogenomics Journal

published in

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

20-29

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/tpj.2009.32

exact match

0 references

cites work

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Pharmacogenetics as a tool in the therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Effects of age and sex on olanzapine plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Pharmacogenetics of antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

High-speed genotyping of CYP1A2*1F mutation with fluorescent hybridization probes using the LightCycler.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

5-HT2A receptor and bipolar affective disorder: association studies in affected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

PCR detection of the TaqA RFLP at the DRD2 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Association of a human G-protein beta3 subunit variant with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

Effect of Caffeine Intake 12 or 24 Hours Prior to Melatonin Intake and CYP1A2*1F Polymorphism on CYP1A2 Phenotyping by Melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.32

21 January 2018

Identifiers

DOI

10.1038/TPJ.2009.32

1 reference

17 December 2017

Dimensions Publication ID

1048086007

0 references

1 reference

17 December 2017